Sinomab Bioscience Limited reported no change in its share capital for the month ended 31 March 2026. The number of issued ordinary shares remained at 1.39 billion, and the company held no treasury shares.

Under the 2022 Share Option Scheme, 11.57 million share options were granted during the month, increasing outstanding options to 80.58 million. No options were exercised, and no new shares were issued or funds raised. Shares that could potentially be issued from existing options stood at 16.93 million, while an additional 40.95 million shares may be issued upon future grants under the same scheme.

Sinomab confirmed compliance with the Hong Kong Stock Exchange’s 25% minimum public-float requirement and filed all necessary regulatory confirmations. The monthly return was submitted on 8 April 2026 by Executive Director, Chairman, and CEO Shui On Leung.